Dr David Reddy has been appointed MMV's new CEO by the Board of Directors, effective 1 January 2011.
David is a New Zealand / Swiss dual national, with 20 years of experience in the development and commercialization of medicines for the treatment of infectious diseases. Most recently, he was the Influenza Pandemic Taskforce Leader for Roche, based at its headquarters in Basel, Switzerland. Prior to that he was the Leader for Roche's HIV franchise, where he led teams responsible for developing HIV therapies and was involved in establishing policies and initiatives to increase access to AIDS care in the developing world. David has a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand.
David will succeed Dr Dennis Schmatz, ad-interim CEO for MMV. The Board of MMV sincerely thanks Dennis for the significant contribution he has made to MMV since the departure of its former CEO, Chris Hentschel, in March 2010. Dennis will be relocating to the US with his family, but will remain engaged with MMV through his role as a Board member and as the Chair of its scientific advisory group.
The Board wishes David and the whole team at MMV every success in their mission to develop a strong pipeline of drugs to address the needs of people suffering from malaria in the world's developing nations.